Elanco Animal Health (NYSE:ELAN) Issues FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.000-1.060 for the period, compared to the consensus earnings per share estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.0 billion, compared to the consensus revenue estimate of $4.9 billion. Elanco Animal Health also updated its Q1 2026 guidance to 0.330-0.36 EPS.

Elanco Animal Health Trading Down 1.0%

Shares of ELAN opened at $24.72 on Tuesday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $23.90 and a 200 day moving average price of $21.55. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $26.08. The firm has a market capitalization of $12.28 billion, a P/E ratio of 412.07, a P/E/G ratio of 3.73 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Sell-side analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on ELAN shares. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. UBS Group raised their target price on Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Finally, Morgan Stanley upped their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.89.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,500 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the acquisition, the insider directly owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 43,450 shares of company stock worth $937,883. Corporate insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Moors & Cabot Inc. bought a new position in shares of Elanco Animal Health in the 3rd quarter worth $206,000. Kotler Kevin acquired a new position in Elanco Animal Health in the fourth quarter valued at about $205,000. Kestra Advisory Services LLC bought a new position in Elanco Animal Health during the fourth quarter worth about $168,000. Empowered Funds LLC grew its position in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares during the period. Finally, Cresset Asset Management LLC grew its position in shares of Elanco Animal Health by 12.8% during the 2nd quarter. Cresset Asset Management LLC now owns 11,338 shares of the company’s stock worth $162,000 after buying an additional 1,287 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.